Novo Nordisk

Showing 15 posts of 176 posts found.

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023
Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent global childhood obesity, which is …

Novo Nordisk launches Wegovy in the UK

September 4, 2023
Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

August 31, 2023
Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …


Novo Nordisk’s Wegovy reduces risk of cardiovascular events

August 9, 2023
Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide

Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …

Novo Nordisk invests DKK 15.9bn to expand API production in Denmark

June 13, 2023
Manufacturing and Production APIs, Chronic Diseases, Novo Nordisk, chronic diseases

Danish healthcare company Novo Nordisk has announced that it will invest another DKK 15.9bn into expanding an existing Active Pharmaceutical …


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

June 7, 2023
Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …

Novo Nordisk to expand obesity study into oral treatment

April 22, 2021
Novo Nordisk, obesity

Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, expanding on its Phase IIIa …

Novo Nordisk obesity treatment successful in clinical trials

March 24, 2021
Research and Development Novo Nordisk, obesity

New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …


FDA approves Novo Nordisk’s Saxenda for adolescent obesity

December 7, 2020
Sales and Marketing FDA, Novo Nordisk, saxenda

The FDA has awarded US approval to Novo Nordisk’s Saxenda (liraglutide) 3mg injection to treat obesity in patients between the …


NICE recommends Novo’s liraglutide for management of obesity and non-diabetic hyperglycaemia

October 30, 2020
Medical Communications, Sales and Marketing NICE, Novo Nordisk, liraglutide

Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made …


Novo Nordisk launches new Rybelsus pill for type 2 diabetes in the UK

September 2, 2020
Research and Development Novo Nordisk, diabetes, type 2, type 2 diabetes

Novo Nordisk’s new type 2 diabetes treatment Rybelsus is now available for doctors and physicians in the UK to prescribe …


European approval for Novo’s Rybelsus to control blood sugar in type 2 diabetes

April 6, 2020
Sales and Marketing Novo Nordisk, Rybelsus, diabetes, pharma

The European Commission has greenlighted Novo Nordisk’s Rybelsus (oral semaglutide) as an adjunct to diet and exercise to improve glycaemic …


Novo Nordisk halts three haemophilia studies after participants suffer thrombotic events

March 17, 2020
Manufacturing and Production, Research and Development Novo Nordisk, haemophilia, pharma

Novo Nordisk has moved to temporarily shut down two of its Phase 3 and one of its Phase 2 clinical …

NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use

January 27, 2020
Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda

NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …


Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

January 17, 2020
Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …

Latest content